The company expects the European Commission (EC) to make a final decision on the marketing authorization in June 2025.

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Amsterdam, the Netherlands Tuesday, April 29, 2025, 10:00 Hrs [IST] ...

View Halozyme Therapeutics, Inc. (HALO) current and estimated P/E ratio data provided by Seeking Alpha.

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...